Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694826 | 1.00 | TDP1 (0.38) | TDP1TP53KDM4EPIK3CGTHRB | |
| SCHEMBL12944742 | 0.81 | CYP2A6 (0.34) | TDP1KDM4ETHRB | |
| SCHEMBL30694818 | 0.81 | KDM4E (0.34) | TDP1KDM4EPIK3CG | |
| SCHEMBL25370593 | 0.81 | KDM4E (0.34) | TDP1KDM4EPIK3CG | |
| SCHEMBL501499 | 0.80 | AKR1C3 (0.39) | TDP1TP53KDM4ETHRB | |
| SCHEMBL501498 | 0.80 | AKR1C3 (0.39) | TDP1TP53KDM4ETHRB | |
| SCHEMBL2262582 | 0.80 | KDM4E (0.43) | TDP1KDM4ETHRB | |
| SCHEMBL1823353 | 0.80 | KDM4E (0.43) | TDP1KDM4ETHRB | |
| SCHEMBL25369080 | 0.78 | KDM4E (0.38) | TDP1KDM4EPIK3CG | |
| SCHEMBL25368970 | 0.78 | KDM4E (0.34) | TDP1KDM4EPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4301752-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| CN-117295736-A | Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof | 剑桥实业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| WO-2022185041-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | TDP1 1582/4885TP53 270/4885KDM4E 1845/4885 |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | ABCB11, CEL, NDC1 | TDP1 2312/4885TP53 2140/4885KDM4E 2268/4885 |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | TDP1 1582/4885TP53 270/4885KDM4E 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.